Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Apr;8(7):517.
doi: 10.21037/atm.2020.01.65.

Keynote 42: Pembrolizumab, PD-L1, and where to draw the line

James Isaacs  1 , Jeffrey Clarke  1 , Neal Ready  1
Affiliations
Editorial

Keynote 42: Pembrolizumab, PD-L1, and where to draw the line

James Isaacs et al. Ann Transl Med. 2020 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm.2020.01.65). NR: Advisory role with Merck, BMS, AZ, Genentech, AbbVie, Celgene; JC: Speaking role with Merck, Advisory role with AstraZeneca, Guardant, Merck, Eli Lilly, Pfizer, and NGM Biopharmaceuticals. Travel compensation from Merck, AstraZeneca, Pfizer, and NGM bio. Board of Directors-Lung Cancer Initiative of North Carolina (uncompensated). Trial PI for: Bristol-Myers Squibb, Eli Lilly, Genentech, Spectrum, Adaptimmune, Medpacto, Bayer, AbbVie, Moderna, GlaxoSmithKline, Array, and AstraZeneca. JI has no conflicts of interest to declare.

Comment on

References

    1. Garon EB, Hellmann MD, Rizvi NA, et al. Five-Year Overall Survival for Patients With Advanced NonSmal. Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. J Clin Oncol 2019;37:2518-27. 10.1200/JCO.19.00934 - DOI - PMC - PubMed
    1. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016;387:1540-50. 10.1016/S0140-6736(15)01281-7 - DOI - PubMed
    1. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2016;375:1823-33. 10.1056/NEJMoa1606774 - DOI - PubMed
    1. Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 2019;393:1819-30. 10.1016/S0140-6736(18)32409-7 - DOI - PubMed
    1. Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med 2018;378:2078-92. 10.1056/NEJMoa1801005 - DOI - PubMed